
PINOVA Capital takes a participation in Hemoteq AG
PINOVA Capital has invested in medical technology company Hemoteq AG in Würselen.
As part of the transaction, CFO Thomas Löwen also acquires a stake in the company.
Hemoteq is a specialist in the market for biocompatible and drug eluting surfaces.
The company develops ultra-thin functional coatings and surface modification solutions for medical devices, supports its customers in obtaining regulatory approval and provides clean room capacities for volume production.
Its products focus on applications in cardiology, ophthalmology, orthopedics and dentistry.
Hemoteq's customer base includes European, North American and Asian medical device manufacturers. The company was founded in 1999.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater